scid

Liarozole (R75251 dihydrochloride) is a cytochrome P450 (CYP450) dependent inhibitor, orally active, it also a potent inhibitor of estrogen (via inhibition of aromatase) and testicular androgen synthesis (inhibition of 17 ,20-lyase).Liarozole dihydrochloride is an imidazole derivative; it is being investigated as a non-hormonal agent in prostate cancer and in the treatment of various other cancers and skin disorders.

Avatrombopag (YM477) is a new oral thrombopoietin (TPO) receptor agonist, activating TPO receptor and increasing megakaryocytic proliferation/differentiation and platelet production.

FGFR1/DDR2 inhibitor 1 is an inhibitor of discoidin domain receptor 2 (DDR2) and fibroblast growth factor receptor 1 (FGFR1), with IC50 values of 31.1 nM, 108.4 nM, and 3.2 nM for FGFR1, KG-1, and DDR2, respectively.

Ecteinascidin 770 inhibits SARS-CoV-2 and Mycobacterium tuberculosis by inhibiting cancer cell viability through RDRP1 (RNA-dependent RNA polymerase 1).

Ecteinascidins are a family of tetrahydroisoquinoline alkaloids known for their antitumor and antimicrobial activities. [Ecteinascidin-Analog-1] is a valuable intermediate for the synthesis of Ecteinascidin analogues.

Piscidic acid is a useful organic compound for research related to life sciences and the catalog number is T124820.

Ascididemin can be regarded as a fused phenanthroline with quinoline.

Viscidulin I, a natural product found in Scutellaria baicalensis, exhibits distinct chemical properties.

TP4 (Nile tilapia piscidin) is an orally active, piscidin-like antimicrobial peptide that inhibits various gram-positive and gram-negative bacterial strains with a minimum inhibitory concentration (MIC) ranging from 0.03 to 10 μg/mL. It demonstrates hemolytic activity and promotes immune response, antioxidant activity, and intestinal health in the presence of bacterial infections. Additionally, TP4 has an anti-tumor effect and induces necrosis in cancer cells by triggering mitochondrial dysfunction [1] [2] [3].

Tilapia piscidin 3, an antimicrobial peptide, exhibits antibacterial properties effective against both gram-positive and gram-negative bacteria. It has demonstrated minimum inhibitory concentrations (MICs) of 2.44 µg/mL for V. vulnificus 204 and V. alginolyticus, 9.78 µg/mL for S. agalactiae 819, 19.55 µg/mL for E. faecalis BCRC 10066, and 0.61 µg/mL for S. agalactiae BCRC 10787. Additionally, it presents hemolytic activity on fish red blood cells [1].

Viscidulin III (Ganhuangenin) is present in Scutellaria baicalensis and acts as an α-glucosidase inhibitor.

Piscidinol A is toxic against the 4T1 and HEp2 cancer cell lines, the IC50 of 8.0 ± 0.03 and 8.4 ± 0.01 uM, respectively. It can inhibit NO production in mouse peritoneal macrophages with inhibitory ratios ranging from 39.8±7.7 to 68.2±4.5%.

Viscidulin II can be potential therapeutic agents against P. acnes-induced skin inflammation, it can significantly suppress P. acnes-induced IL-8 and IL-1β production in THP-1 cells, concomitant intradermal injection of viscidulin II with P. acnes can effectively attenuate P. acnes-induced ear swelling, and decrease the production of IL-6 and tumor necrosis factor-α in ear homogenates.

Viscidulin III tetraacetate is a natural product for research related to life sciences. The catalog number is TN5239 and the CAS number is 96684-81-0.

Piscidin-1 (22-42) is a highly potent, multifunctional Antimicrobial Peptide (AMP) produced by the Orange-spotted grouper (Epinephelus coioides).

Piscidin-1 (22-42) (TFA) is a highly potent, multi-functional Antimicrobial Peptide (AMP) produced by Orange-spotted grouper (Epinephelus coioides).

Niclosamide (Niclocide)(BAY2353) is used to treat most tapeworm infections by inhibiting DNA replication.

Trabectedin (Ecteinascidin 743) has potent antitumor activity and the potential for soft tissue sarcoma and ovarian cancer research. Trabectedin inhibits cell growth of MX-1, MCF7 and MCF7/DXR cells with IC50 values of 0.1 nM, 1.5 nM and 3.7 nM, respectively.

Cimicifugic acid E (2-E-Feruloylpiscidic acid) is a ferulic acid ester compound identified in Cimicifuga racemosa. It shows potential for research into menopause syndrome.

Cimicifugic acid D (2-Caffeoylpiscidic acid) is a benzyl tartaric acid ester that can induce vasorelaxation and an endothelium-dependent relaxation mechanism in pre-constricted rat aortic strips. During norepinephrine-induced contractions in rat aortic strips, Cimicifugic acid D inhibits extracellular Ca2+ influx through receptor-operated Ca2+ channels (ROC), while it does not affect voltage-dependent Ca2+ channels (VDC) or K+-induced contractions.

CT-2584 is an anticancer agent that inhibits phospholipid signaling and kills tumor cells through the production of reactive oxygen intermediates. CT-2584 reduces NKEF-B expression in several tumor cell types. CT-2584 reduced tumor growth in SCID mice by causing shunting of ab initio phospholipid biosynthesis from phosphatidylcholine (PC) to phosphatidylinositol (PI) via PA.

4-Aminobenzamidine dihydrochloride (p-Aminobenzamidine dihydrochloride) is a strong trypsin inhibitor and a relatively weak inhibitor of urokinase type plasminogen activator (uPA) (K i =82 μM). 4-Aminobenzamidine can inhibit growth of a human prostate tumor in SCID mice [1] [2].

Compound MX69-102 is an MDM-2/p53 inhibitor that promotes MDM2 degradation, resulting in the activation of p53 and the apoptosis of cancer cells. It demonstrates effective inhibition against human MDM2-overexpressing ALL xenograft tumors in SCID mice.

ART838 is a dimeric pimeloyl urea compound notable for its potent anti-leukemic activity and favorable pharmacological properties. In vitro, ART-838 exhibits submicromolar inhibitory concentrations against all leukemia cell lines, demonstrating anti-leukemic efficacy 88 times greater than artemether. This compound remains in the body for extended periods and works synergistically with other anti-leukemic agents and novel kinase inhibitors to suppress leukemia cell growth. In immunodeficient NOD-SCID-IL2Rgnull (NSG) mice, ART-838 attains a plasma half-life longer than that of artemether, sustaining effective anti-leukemic concentrations for over 8 hours. Intermittent ART-838 treatment notably inhibited the growth of acute leukemia xenografts and primary grafts in NSG mice, surpassing the efficacy of artemether.